Brickell Biotech Inc. (NASDAQ:BBI) went up by 3.99% from its latest closing price compared to the recent 1-year high of $2.61. The company’s stock price has collected 5.80% of gains in the last five trading sessions. Press Release reported on 06/01/21 that Brickell Biotech Announces Publication of Japan Phase 3 Long-Term Safety and Efficacy Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK(R)) in the Journal of Dermatology
Is It Worth Investing in Brickell Biotech Inc. (NASDAQ :BBI) Right Now?
Plus, the 36-month beta value for BBI is at 0.17. Opinions of the stock are interesting as 2 analysts out of 2 who provided ratings for Brickell Biotech Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $5.50. BBI currently public float of 65.67M and currently shorts hold a 6.28% ratio of that float. Today, the average trading volume of BBI was 1.39M shares.
BBI’s Market Performance
BBI stocks went up by 5.80% for the week, with a monthly jump of 1.90% and a quarterly performance of -17.28%, while its annual performance rate touched -33.58%. The volatility ratio for the week stands at 4.23% while the volatility levels for the past 30 days are set at 6.07% for Brickell Biotech Inc.. The simple moving average for the period of the last 20 days is 6.65% for BBI stocks with a simple moving average of -2.02% for the last 200 days.
Analysts’ Opinion of BBI
Many brokerage firms have already submitted their reports for BBI stocks, with Lake Street repeating the rating for BBI by listing it as a “Buy.” The predicted price for BBI in the upcoming period, according to Lake Street is $6 based on the research report published on August 28th of the previous year 2020.
Oppenheimer, on the other hand, stated in their research note that they expect to see BBI reach a price target of $5. The rating they have provided for BBI stocks is “Outperform” according to the report published on August 25th, 2020.
BBI Trading at -2.49% from the 50-Day Moving Average
After a stumble in the market that brought BBI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.14% of loss for the given period.
Volatility was left at 6.07%, however, over the last 30 days, the volatility rate increased by 4.23%, as shares sank -0.13% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.76% lower at present.
During the last 5 trading sessions, BBI rose by +5.80%, which changed the moving average for the period of 200-days by +9.63% in comparison to the 20-day moving average, which settled at $0.8531. In addition, Brickell Biotech Inc. saw 16.58% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at BBI starting from Chadha Deepak, who purchase 12,500 shares at the price of $0.83 back on May 19. After this action, Chadha Deepak now owns 78,167 shares of Brickell Biotech Inc., valued at $10,378 using the latest closing price.
Chadha Deepak, the Chief Research & Dev. Officer of Brickell Biotech Inc., purchase 2,700 shares at $0.82 during a trade that took place back on May 18, which means that Chadha Deepak is holding 65,667 shares at $2,212 based on the most recent closing price.
Stock Fundamentals for BBI
Current profitability levels for the company are sitting at:
- -1151.26 for the present operating margin
The net margin for Brickell Biotech Inc. stands at -1147.80. The total capital return value is set at -118.61, while invested capital returns managed to touch -119.75. Equity return is now at value -108.80, with -81.70 for asset returns.
Based on Brickell Biotech Inc. (BBI), the company’s capital structure generated 1.88 points at debt to equity in total, while total debt to capital is 1.85. Total debt to assets is 1.52, with long-term debt to equity ratio resting at 0.54. Finally, the long-term debt to capital ratio is 0.53.
When we switch over and look at the enterprise to sales, we see a ratio of -5.75, with the company’s debt to enterprise value settled at -0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.28.